Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel relapse prevention study in major depressive disorder
2018-000064-28Phase 3Terminated
- Sponsor
- Allergan
- Start
- Sep 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rapastinel in major depressive disorder (MDD) (3 arms), sponsored by Allergan. Primary endpoint: Time to first relapse during the double-blind treatment period. Started Sep 2018; status: terminated.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-000064-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000064-28.